Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes
mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.